astrazeneca-istock-458250071-fotonen-

Fotonen / iStockphoto.com

31 March 2017Americas

District court upholds AstraZeneca’s migraine drug patents

The US District Court for the District of Delaware has upheld AstraZenca’s patents protecting Zomig (zolmitriptan) in a dispute with generic manufacturer Lannett.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case